Skip to Main Content
Table 4—

Prediction of newly developed microvascular complications subdivided into three skin autofluorescence (AF) groups

Microvascular complicationn*Skin AF <2.35 AU2.35 ≤ Skin AF <3.00 AUSkin AF ≥3.00 AU
Retinopathy 708 15/241 (6.2) 18/251 (7.2) 28/216 (13.0) 
Neuropathy 662 11/219 (5.0) 27/247 (10.9) 28/196 (14.3) 
(Micro)albuminuria 657 18/225 (8.0) 31/253 (12.3) 38/179 (21.2) 
Any 431 23/161 (14.3) 41/167 (24.6) 45/103 (43.7) 
Microvascular complicationn*Skin AF <2.35 AU2.35 ≤ Skin AF <3.00 AUSkin AF ≥3.00 AU
Retinopathy 708 15/241 (6.2) 18/251 (7.2) 28/216 (13.0) 
Neuropathy 662 11/219 (5.0) 27/247 (10.9) 28/196 (14.3) 
(Micro)albuminuria 657 18/225 (8.0) 31/253 (12.3) 38/179 (21.2) 
Any 431 23/161 (14.3) 41/167 (24.6) 45/103 (43.7) 

Data are n (%) of newly developed microvascular complications of subgroups compared with the group who did not develop a microvascular complication.

*

Patients who did not have a complication at baseline. Subgroups of skin AF are tertiles rounded to a practical level.

Close Modal

or Create an Account

Close Modal
Close Modal